For decades, the textbook answer was final: once severed, nerve pathways in the brain and spinal cord do not grow back. Paralysis was considered irreversible. A team at the University of Cambridge has now published evidence that directly challenges that assumption, using a lab-grown model built entirely from human stem cells.
The work, led by Andras Lakatos, centers on tiny, pea-sized organoids — miniature versions of the brain and spinal cord. Researchers grew these structures separately, then watched as nerve fibers called axons extended from the brain tissue, crossed an empty gap, and made functional connections with the spinal cord tissue.
Those connections were strong enough to trigger muscle contractions. That alone would be remarkable. But the study, published in the journal Cell Reports, goes further.
It identifies a biological clock inside human neurons. The team found that young neurons could repair damaged axons up to roughly day 150 of development.
After that point, a genetic switch embedded in maturing human cells sharply reduced their ability to regenerate. This was not a matter of injury severity or scar tissue. It was a built-in, programmed loss of capacity.
By mapping the gene network behind that switch, the researchers identified key regulators. When they blocked those regulators, the neurons regained their ability to grow axons. An existing drug, lynestrenol, was found to improve axon regrowth in tests.
The researchers caution that lynestrenol is unlikely to be the final clinical answer, but it proves a principle: human neurons can be directly targeted and persuaded to regenerate. This matters because most earlier research relied on rodents.
Mouse and rat neurons do not behave exactly like human neurons. The difference is not trivial. A treatment that works in a mouse spinal cord often fails in a human one.
The Cambridge model sidesteps that problem entirely. It uses human tissue from the start.
The implications reach across several devastating conditions. Spinal cord injury is the obvious one. But the same regenerative failure underlies motor neurone disease and multiple sclerosis.
In all three, the core problem is the same: axons die and do not come back. Lakatos’s team has shown that the blockage is not absolute. It is controlled by a switch that can be flipped.
The practical path from lab discovery to clinic is long. But the fundamental barrier — the idea that human central nervous system damage is permanently irreversible — has been broken.
What the Cambridge team has done is build a test system that is both human and functional. A pea-sized brain and spinal cord, grown from stem cells, forming working circuits. That system let them watch regeneration happen, then stop, then happen again after they blocked the genetic brakes.
No one is claiming a cure tomorrow. Lynestrenol is a starting point, not a finish line.
But the discovery that the regenerative ability is there, hidden but intact, waiting on a genetic switch, changes the terms of the search. The question is no longer whether human neurons can regrow. It is how to keep the switch flipped on.
